Trump Live Updates: FDA Peptide Meetings, Tariffs and Latest News
The Trump administration has launched a series of significant policy shifts and legal challenges this week, impacting trade relations and federal oversight. President Trump issued an executive order requiring warning signs outside the Smithsonian National Museum of American History, alleging the institution presents inaccurate historical accounts and exhibits signs of radical political activism. This directive adds to ongoing congressional tension regarding the museum’s management and its presentation of American history.
In the realm of international trade, the administration has implemented new tariffs ranging from 10 to 12.5 percent on imports from over 80 countries, including members of the European Union, Canada, and Mexico. These duties follow the expiration of a previous tariff regime and are justified by the administration as a response to foreign trade practices. Legal challenges have already emerged, as small businesses filed lawsuits questioning the executive authority behind these new measures in the federal trade court.
Simultaneously, an FDA advisory panel has recommended broader access to several unproven peptide treatments. These substances, often marketed by wellness and telehealth companies for longevity and performance enhancement, have sparked concerns among federal scientists regarding safety and clinical effectiveness. Health Secretary Robert F. Kennedy Jr. has reportedly expressed interest in these treatments, despite resistance from internal agency experts who warn about the lack of rigorous testing and potential health risks associated with a lighter regulatory approach.
Additionally, the White House continues to maintain a significant presence in Washington with the continued deployment of National Guard troops. A recent contract award for housing units suggests that this operational posture will persist through the remainder of the president’s term. These developments reflect the administration’s broader strategy of asserting federal control over cultural and economic policy while navigating high-stakes legal battles.